In alignment with professional recommendations, GLP-1 RAs are prioritized in patients with established atherosclerotic cardiovascular disease (such as coronary artery disease, stroke, or peripheral artery disease) and significant excess body weight. The gene discussed is GCG; the disease is peripheral arterial disease.